Pancreatic VIPomas: Subject Review and One Institutional Experience

• Published in: Journal of gastrointestinal surgery Vol. 12; no. 2; pp. 382 - 393
• Main Authors: Ghaferi, Amir A., Chojnacki, Karen A., Long, William D., Cameron, John L., Yeo, Charles J.
• Format: Journal Article
• Language: English
• Published: New York Springer-Verlag 01-02-2008; Springer Nature B.V
• Subjects: Algorithms; Cancer; Diagnosis, Differential; Diarrhea - etiology; Gastroenterology; Humans; Liver Neoplasms - secondary; Medicine; Medicine & Public Health; Pancreas; Pancreatectomy; Pancreatic Neoplasms - diagnostic imaging; Pancreatic Neoplasms - pathology; Pancreatic Neoplasms - surgery; Surgery; Tomography; Tomography, X-Ray Computed; Vasoactive Intestinal Peptide - blood; Vipoma - diagnostic imaging; Vipoma - pathology; Vipoma - surgery; VIPomas; Diarrhea; Primary pancreatic tumor
• ISSN: 1091-255X; 1873-4626
• DOI: 10.1007/s11605-007-0177-0

VIPomas are rare pancreatic endocrine tumors associated with a well-defined clinical syndrome characterized by watery diarrhea, hypokalemia, and metabolic acidosis. The objective of this study was to review a single institution’s experience with VIPomas, as well as to review the English literature. A retrospective review of the Johns Hopkins pancreatic database revealed four cases of VIPoma, with three patients being male. All patients presented with watery diarrhea, hypokalemia, hypercalcemia, and acidosis. All patients had no family history of multiple endocrine neoplasia. Computed tomography revealed the primary pancreatic tumor in all patients, with three tumors located in the tail of the pancreas. One tumor involved the entire pancreas. Computed tomography and/or octreotide radionuclide scans identified hepatic metastasis in three patients. Mean serum vasoactive intestinal polypeptide levels were 683 pg/ml (range 293 to 1,500 pg/ml). All patients underwent resection of the pancreatic primary tumor. Two patients also had simultaneous liver resections. All patients had evidence of malignancy as defined by the presence of metastatic lymph nodes and/or hepatic metastases. Two patients had complete resolution of symptoms after surgical resection. One patient required radioablation of liver metastases and adjuvant octreotide therapy for control of symptoms. One patient died of progressive metastatic disease 96 months after surgery, whereas the other three remain alive. Extended, meaningful survival can be achieved for VIPoma patients, combining an aggressive surgical approach with additional strategies for treatment of unresected disease.